Fore Biotherapeutics · Regulatory · plixorafenib (PLX120-03 / FORTE)

Pilocytic Astrocytoma — Summary & References

Base document: "Pilocytic Astrocytoma Summary Literature Only" (H. Guiney draft) Prepared: 11 Aug 2026 Classification: Internal — Confidential

About this format — supports CTD Module 2.5.1

This is a disease-background reference, and its role in a marketing application is to be the evidence base behind Section 2.5.1, Product Development Rationale — the opening section of the Module 2.5 Clinical Overview under ICH M4E(R2). 2.5.1 must identify the disease and population, summarise current therapy and its limitations, state the unmet medical need, and give the scientific rationale linking mechanism to need.

2.5.1 itself is short and argumentative; it cannot carry this level of detail, but every figure it uses has to be traceable to something that can. That is what this document is. The consolidated rationale drawing on it lives at 2.5.1 Product Development Rationale.

2.5.1 Product Development Rationale ← evidence base: this document citation register2.7.3 Efficacy2.7.4 Safety

⚠ Decision support — not medical or regulatory advice. Every figure is traced to a named source and its exact location; the base draft's five references were verified against primary sources. Medical + regulatory HITL review required before any external use.

Pilocytic astrocytoma (PA) written to the structure used for DLGNT, PXA, GBM and eGBM: description → subtypes → localization → imaging → epidemiology → genetic profile → grading → WHO criteria → diagnostic checklist, with §P covering the prognostic and treatment content that carries the program relevance. Sources are tagged Base draft when carried from the supplied summary and its reference list, and Added where a primary source was retrieved to verify or extend it.

Why PA matters most of the five. PA is the archetypal KIAA1549::BRAF fusion tumor — the same fusion that defines DLGNT. It is therefore the histology where the distinction between a type I RAF inhibitor and a paradox-breaking agent is most consequential, and it is the only one of the five with an already-approved BRAF-targeted competitor in its V600E subgroup. See §P4.

1 · Description

A CNS WHO grade 1 circumscribed astrocytic glioma occurring predominantly in children and young adults, though it may occur across the age spectrum. Histologically PA shows a biphasic pattern of compact and loose/myxoid areas, piloid ("hair-like") cells, low proliferative activity, Rosenthal fibers and eosinophilic granular bodies — with the important caveat that individual histologic features may be variably present Base draft WHO 2021.

PA is defined biologically by MAPK-pathway activation, most commonly through KIAA1549::BRAF fusion; BRAF V600E and other MAPK-pathway alterations occur less frequently Base draft WHO 2021.

2 · Subtypes

The clinically decisive division is not morphologic but molecular: KIAA1549::BRAF fusion vs BRAF V600E vs BRAF wild-type. This split drives prognosis (§P1), invasive behaviour (§P2), transformation risk (§P3) and drug selection (§P4) — and it is the axis on which the entire program rationale turns.

Pilomyxoid astrocytoma is the historically related pattern (hypothalamic/chiasmatic, monophasic, myxoid, typically lacking Rosenthal fibers), classically regarded as more aggressive. Not addressed in the base draft; flagged in §5 as requiring a source before use.

3 · Localization

PA may arise anywhere in the neuraxis Base draft WHO 2021:

Cerebellum — most common site
Optic pathway / hypothalamus (the diencephalic tumors, which carry their own prognostic data — §P1)
Brainstem
Cerebral hemispheres
Spinal cord

Localization is prognostically loaded here, not incidental. Site determines resectability, and resectability is the dominant prognostic variable (§P1). Cerebellar PA is frequently curable by resection; optic-pathway/hypothalamic PA frequently is not — which is why the diencephalic subgroup is analysed separately and does worse.

4 · Imaging

Documented gap. The base draft is a literature-only summary and contains no imaging content, and none of its five references is an imaging source. The classic teaching — a cystic cerebellar mass with an enhancing mural nodule, T2-hyperintense, often with enhancement despite grade 1 status — is deliberately not asserted here with a citation, because no retrieved source supports it. An imaging reference must be added before this section can match the DLGNT and PXA slides, both of which carry a full MRI paragraph.

5 · Epidemiology

Measure	Value	Source & location
Age distribution	Predominantly children and young adults; occurs across the age spectrum	Base draft WHO 2021
10-year overall survival (pediatric LGG populations)	>85–90%	Base draft de Blank 2019. Note this is a pediatric LGG figure, not PA-specific — state it as such.
Incidence	Not established in the supplied references	Gap. No incidence rate is given in the base draft or its five references. Do not quote a rate without adding a registry source (CBTRUS would supply it).
Sex distribution	Not addressed	Gap — every other histology in this set carries an M:F figure.

6 · Genetic profile

Alteration	Role	Source & note
KIAA1549::BRAF fusion	Most common MAPK driver	Base draft WHO 2021. Favourable relative to V600E (§P1). Same fusion that defines DLGNT.
BRAF p.V600E	Less frequent; adverse	Base draft WHO 2021. Drives every adverse finding in §P.
CDKN2A deletion	Independent adverse factor	Added Lassaletta 2017 — extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E tumors. Present in 57% of secondary HGG Added Mistry 2015.
Other MAPK alterations	Less frequent	Base draft WHO 2021

7 · Grading

CNS WHO grade 1 — the only grade assigned Base draft WHO 2021. Grade 1 denotes a circumscribed, biologically indolent tumor, but grade 1 is not a synonym for benign outcome: unresectable, residual, recurrent or progressive disease behaves substantially worse (§P1), and a minority undergo malignant transformation (§P3).

8 · WHO diagnostic criteria

A circumscribed astrocytic glioma, CNS WHO grade 1.
Biphasic architecture — compact piloid and loose/myxoid areas — with Rosenthal fibers and/or eosinophilic granular bodies; features may be variably present.
Low proliferative activity.
MAPK-pathway alteration, most commonly KIAA1549::BRAF fusion.

Base draft WHO 2021.

9 · Diagnostic checklist

Step	What to establish
1 · Architecture	Circumscribed, not diffusely infiltrating — this separates PA from diffuse astrocytoma.
2 · Morphology	Biphasic compact/myxoid, piloid cells, Rosenthal fibers, eosinophilic granular bodies. Absence of any one feature does not exclude PA.
3 · Proliferation	Low. High mitotic activity should prompt reconsideration.
4 · Site	Cerebellum most common; record site — it determines resectability and therefore prognosis.
5 · MAPK alteration	Confirm. Most commonly KIAA1549::BRAF fusion.
6 · Distinguish fusion from V600E	The single most consequential step. Determines prognosis, invasive behaviour, transformation risk, and — critically — which class of RAF inhibitor is appropriate (§P4).
7 · CDKN2A status	Independent adverse factor in V600E tumors; add it when V600E is found.
8 · Extent of resection	Record. Independent prognostic variable — and note that GTR does not secure V600E cases (§P2).

P · Prognosis, molecular risk & treatment landscape

P1 · Prognosis is good overall — and markedly worse with BRAF V600E

PA generally has a favourable long-term prognosis, particularly after complete surgical resection, with 10-year OS for pediatric LGG populations generally exceeding 85–90% Base draft de Blank 2019. Long-term disease control is substantially less favourable in unresectable, residual, recurrent or progressive disease.

Population	BRAF V600E	Non-V600E	Source & exact figures
Pediatric LGG 10-year PFS	27% 95% CI 12.1–41.9	60.2% 95% CI 53.3–67.1	Added Lassaletta 2017, JCO — combined clinical/genetic institutional study, n=510, long-term follow-up. Comparator is BRAF wild-type. PDQ states this as "27% … compared with 60%."
Diencephalic low-grade astrocytoma 5-year PFS	22%	52%	Base draft PDQ, verbatim: "children with diencephalic low-grade astrocytomas with a BRAF V600E variant had a 5-year PFS rate of 22%, compared with a PFS rate of 52% in children with wild-type BRAF." PDQ reference [27] — underlying primary not separately identified.

Precision point on the comparator. PDQ and the base draft describe the non-V600E arm as tumors "that did not harbor the BRAF V600E variant (such as those with KIAA1549::BRAF fusions or wild-type BRAF)." Lassaletta 2017 reports the 60.2% figure specifically for BRAF wild-type pediatric LGG. When quoting, say "non-V600E" and cite PDQ, or say "wild-type" and cite Lassaletta — the two are not interchangeable, and a reviewer checking the primary will notice.

P2 · Invasive phenotype — gross-total resection does not secure V600E cases

PDQ, verbatim: "Even in patients who underwent a gross-total resection, recurrence was noted in one-third, suggesting that BRAF V600E tumors have a more invasive phenotype than do other low-grade glioma variants." Base draft PDQ [ref 26 = Lassaletta 2017].

Lassaletta 2017 further found that extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E pediatric LGG Added.

Why this is the most important sentence in the document. Surgery is the preferred initial treatment when complete resection can be safely achieved (§P4) — but in V600E tumors a third recur even after gross-total resection. That is the clinical space a systemic BRAF-directed agent is meant to occupy, and it is a cleaner statement of unmet need than any survival curve.

P3 · Risk of high-grade transformation

PDQ, verbatim: "The frequency of the BRAF V600E variant was significantly higher in pediatric low-grade gliomas that transformed to high-grade gliomas (8 of 18 patients) than was the frequency of the variant in tumors that did not transform to high-grade gliomas (10 of 167 cases)." Base draft PDQ [ref 24].

The underlying population-based analysis Added Mistry 2015, JCO 33(9):1015–22: malignant transformation occurred in 26 of 866 (2.9%) pediatric LGG; among secondary high-grade gliomas, BRAF V600E in 39% and CDKN2A deletion in 57%. All BRAF V600E alterations and 80% of CDKN2A changes were traceable to the antecedent low-grade tumor — i.e. both are early events, present before transformation, not acquired at it.

Reading this correctly. Transformation is uncommon in absolute terms (2.9% of all pediatric LGG) but strongly enriched for V600E. Present both numbers together: quoting 8/18 alone overstates transformation risk for an unselected PA patient; quoting 2.9% alone hides the V600E signal.

P4 · Treatment landscape

Surgery is the preferred initial treatment when complete resection can be safely achieved Base draft PDQ.

Conventional systemic therapy for symptomatic, unresectable or progressive pediatric LGG has been carboplatin ± vincristine, single-agent vinblastine, and TPCV (thioguanine, procarbazine, lomustine, vincristine) Base draft PDQ.

COG A9952 (children without NF1)	5-year EFS	Note
Carboplatin + vincristine	39% ± 4%	P = 0.10 — the difference was NOT statistically significant. Added Ater 2012, JCO 30(21):2641–47.
TPCV	52% ± 5%
Carboplatin + vincristine — NF1 vs non-NF1	69% ± 4% vs 39% ± 4%	P < 0.001 — NF1 patients do markedly better Added Ater 2012 / COG.

Correction to carry into any downstream use. The base draft states "the 5-year event-free survival rate was 39% with carboplatin/vincristine and 52% with TPCV in children without NF1" — both figures are correct, but presented without P = 0.10 they read as a demonstrated TPCV advantage. A9952 did not establish superiority. Any regulatory-facing document must carry the P value; a reviewer will check it. This is the one substantive correction to the base draft.

Molecularly targeted therapy has increasingly altered the landscape for MAPK-driven disease Base draft:

Dabrafenib + trametinib — FDA approved for patients ≥1 year of age with BRAF V600E-mutant pediatric low-grade glioma requiring systemic therapy, and studied against carboplatin/vincristine in the first-line systemic setting Base draft FDA, 16 Mar 2023.
MEK inhibition has also demonstrated activity in pediatric LGG Base draft PDQ.

The program-critical consequence — and the reason PA is different from the other four histologies.
(1) An approved BRAF-targeted competitor already occupies the V600E niche in first-line systemic pediatric LGG. For PA, the V600E space is not open ground — any positioning must be relative to dabrafenib + trametinib.
(2) The larger PA population is fusion-driven, not V600E — KIAA1549::BRAF is the most common alteration. That population is not addressed by the approved V600E indication, and it is where a paradox-breaking agent is mechanistically differentiated, since type I RAF inhibitors are inactive against — and can paradoxically activate — BRAF-fusion tumors.
(3) Read together: the unmet need in PA sits in the fusion population and in V600E tumors that recur after gross-total resection (§P2). That is the sharpest framing of PA's role in the program.

R · References

R1 · Base draft reference list — all five verified

Base draft WHO Classification of Tumours Editorial Board. Central Nervous System Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2021. WHO Classification of Tumours Series, Vol. 6. Used for: §1, 2, 3, 6, 7, 8. Definition, histology, sites, MAPK biology, grade.
Base draft de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019;31(1):21–27. Used for: §5, P1. The >85–90% 10-year OS figure — a pediatric LGG population figure, not PA-specific.
Base draft PDQ Pediatric Treatment Editorial Board. Childhood Astrocytomas and Other Gliomas Treatment (PDQ®) — Health Professional Version. National Cancer Institute. Updated April 14, 2025. cancer.gov. Used for: §P1, P2, P3, P4. Passages verified verbatim against the live PDQ. Note the three BRAF V600E findings trace to three different PDQ references — [26] Lassaletta, [27] diencephalic, [24] transformation — and should not be attributed to a single study.
Base draft Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(21):2641–2647. Used for: §P4. COG A9952 — 5-yr EFS 39%±4% CV vs 52%±5% TPCV, P = 0.10 (not significant).
Base draft U.S. Food and Drug Administration. FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation. March 16, 2023. Used for: §P4. The approved competitor in the V600E niche.

R2 · Added — primary sources behind the PDQ statements

Added Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. J Clin Oncol. 2017;35(25):2934–2941. DOI 10.1200/JCO.2016.71.8726. The primary behind PDQ [26] and the source of the headline figure. n=510. 10-yr PFS 27% (95% CI 12.1–41.9) vs 60.2% (95% CI 53.3–67.1) for BRAF wild-type. Extent of resection and CDKN2A deletion independently adverse.
Added Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015;33(9):1015–1022. The primary behind PDQ [24]. Transformation in 26/866 (2.9%); BRAF V600E in 39% and CDKN2A deletion in 57% of secondary HGG; both traceable to the antecedent low-grade tumor as early events.

Outstanding — needed before this section matches the others. (1) An imaging reference (§4) — the only histology-overview section with no source at all. (2) An incidence and sex-distribution source (§5); every other histology in this set carries both. (3) The primary behind PDQ reference [27] (diencephalic 22% vs 52%), currently citable only through PDQ. (4) A source for pilomyxoid astrocytoma (§2) if that pattern is to be included.

Method & limits. The supplied base draft was read in full (4 content paragraphs + 5 references; the document contains no footnotes part — superscripts are manual markers keyed to the reference list). All four PDQ passages were retrieved from the live NCI PDQ Health Professional Version and are quoted verbatim, with PDQ's own reference numbers preserved. Lassaletta 2017, Mistry 2015 and Ater 2012 were verified independently of PDQ. Confidence intervals and the A9952 P value were added because the base draft omitted them and they change how the figures read. Where the base draft and the primary sources differ in framing — the non-V600E vs wild-type comparator (§P1) and the A9952 significance (§P4) — both are shown and the discrepancy is stated rather than smoothed. Sections 4 and 5 are marked as gaps rather than filled from memory or general knowledge.